Market Cap N/A
Revenue (ttm) 0.00
Net Income (ttm) -82.94M
EPS (ttm) N/A
PE Ratio N/A
Forward PE N/A
Profit Margin N/A
Debt to Equity Ratio N/A
Volume 1,400
Avg Vol 11,350
Day's Range N/A - N/A
Shares Out N/A
Stochastic %K 35%
Beta N/A
Analysts Strong Buy
Price Target N/A

Company Profile

NKGen Biotech, Inc., a clinical-stage biotechnology company, develops and commercializes cell therapies for neurodegenerative and oncological diseases based on activated natural killer (NK) cells in the United States. The company develops SNK01, an autologous NK cell therapy candidate in Phase I/IIa trial for the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease; and SNK02, which consists of an allogenic NK cell therapy that has completed Phase 1 trial and a HE...

Industry: Biotechnology
Sector: Healthcare
Phone: 949-396-6830
Address:
3001 Daimler Street, Santa Ana, United States
Latest News on NKGNW
No data available.